Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit By: MindMed via Business Wire September 14, 2023 at 07:30 AM EDT Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 20, 2023 at 11:00 a.m. ET, which is being hosted virtually. The webcast of the panel discussion will be accessible to those registered to attend the summit. About MindMed MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. View source version on businesswire.com: https://www.businesswire.com/news/home/20230914966700/en/Contacts For Media & Investor Inquiries, please contact: Maxim Jacobs, CFA Vice President, Investor Relations and Corporate Communications Mind Medicine (MindMed) Inc. ir@mindmed.co media@mindmed.co Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit By: MindMed via Business Wire September 14, 2023 at 07:30 AM EDT Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 20, 2023 at 11:00 a.m. ET, which is being hosted virtually. The webcast of the panel discussion will be accessible to those registered to attend the summit. About MindMed MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. View source version on businesswire.com: https://www.businesswire.com/news/home/20230914966700/en/Contacts For Media & Investor Inquiries, please contact: Maxim Jacobs, CFA Vice President, Investor Relations and Corporate Communications Mind Medicine (MindMed) Inc. ir@mindmed.co media@mindmed.co
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 20, 2023 at 11:00 a.m. ET, which is being hosted virtually. The webcast of the panel discussion will be accessible to those registered to attend the summit. About MindMed MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. View source version on businesswire.com: https://www.businesswire.com/news/home/20230914966700/en/
For Media & Investor Inquiries, please contact: Maxim Jacobs, CFA Vice President, Investor Relations and Corporate Communications Mind Medicine (MindMed) Inc. ir@mindmed.co media@mindmed.co